← Leaderboards
Alexander Karpeisky
Mbc Pharma, Inc.
$2,731,438
Attributed
$2,731,438
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2007–13$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$2,731,438 · 3
By mechanism
R44$2,631,438 · 2
R43$100,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorCancer PatientPathological FractureQuality Of LifeLesionBisphosphonateCessation Of LifeMouse ModelPreparationPreventMalignant NeoplasmsTumor BurdenHypercalcemiaDoseBone PainBone DiseasesLeadBaseIn VivoClinical ApplicationChemotherapyAntineoplastic AgentsChemotherapeutic AgentInorganic Phosphate
Grant awards (6)
Novel bisphosphonates for prostate cancer therapy$77,875
R44 · FY2013 · CA · contact PI
Novel bisphosphonates for prostate cancer therapy$1,070,889
R44 · FY2011 · CA · contact PI
Novel bisphosphonates for prostate cancer therapy$724,165
R44 · FY2010 · CA · contact PI
Novel bisphosphonates for multiple myeloma therapy$366,723
R44 · FY2009 · CA · contact PI
Novel bisphosphonates for multiple myeloma therapy$391,786
R44 · FY2008 · CA · contact PI
Novel bisphosphonates for prostate cancer therapy$100,000
R43 · FY2007 · CA · contact PI